A potent dimeric peptide antagonist of interleukin-5 that binds two interleukin-5 receptor α chains

被引:44
|
作者
England, BP
Balasubramanian, P
Uings, I
Bethell, S
Chen, MJ
Schatz, PJ
Yin, Q
Chen, YF
Whitehorn, EA
Tsavaler, A
Martens, CL
Barrett, RW
McKinnon, M
机构
[1] Affymax Res Inst, Palo Alto, CA 94304 USA
[2] Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Cell Biol Unit, Stevenage SG1 2NY, Herts, England
[3] Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Prot Sci Unit, Stevenage SG1 2NY, Herts, England
关键词
D O I
10.1073/pnas.110053997
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Two series of peptides that specifically bind to the extracellular domain of the alpha chain of the human interleukin-5 receptor (IL-5R alpha). but share no primary sequence homology to IL-5, were identified from libraries of random recombinant peptides. Affinity maturation procedures generated a 19-aa peptide that binds to the IL-5 receptor alpha/beta heterodimer complex with an affinity equal to that of IL-5 and is a potent and specific antagonist of IL-5 activity in a human eosinophil adhesion assay. The active form of the peptide is a disulfide-crosslinked dimer that forms spontaneously in solution. Gel filtration analysis, receptor-binding studies, and analytical ultracentrifugation reveal that the dimeric peptide binds simultaneously to two receptor alpha chains in solution. Furthermore, the dimer peptide, but not IL-5, can activate a chimeric receptor consisting of the IL-5R alpha extracellular domain fused to the intracellular domain of the epidermal growth factor receptor, thus demonstrating that the peptide also promotes receptor dimerization in a cellular context. The functional antagonism produced by the bivalent interaction of the dimeric peptide with two IL-5R alpha chains represents a distinctive mechanism for the antagonism of cytokines that use heteromeric receptors.
引用
收藏
页码:6862 / 6867
页数:6
相关论文
共 50 条
  • [31] Interleukin-5 in the Pathophysiology of Severe Asthma
    Pelaia, Corrado
    Paoletti, Giovanni
    Puggioni, Francesca
    Racca, Francesca
    Pelaia, Girolamo
    Canonica, Giorgio Walter
    Heffler, Enrico
    FRONTIERS IN PHYSIOLOGY, 2019, 10
  • [32] Therapeutic effects of antibodies to interleukin-5
    Cuss, FM
    ALLERGY, 1998, 53 : 89 - 92
  • [33] Interleukin-5 and human B lymphocytes
    Baumann, MA
    Paul, CC
    METHODS-A COMPANION TO METHODS IN ENZYMOLOGY, 1997, 11 (01): : 88 - 97
  • [34] Eosinophils and interleukin-5 - The debate continues
    Kay, AB
    Menzies-Gow, A
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (12) : 1586 - 1587
  • [35] Eosinophilia and intracranial worm recovery in interleukin-5 transgenic and interleukin-5 receptor α chain-knockout mice infected with Angiostrongylus cantonensis
    Hiroko Sugaya
    Mikiko Aoki
    Toshimi Yoshida
    Kiyoshi Takatsu
    Kentaro Yoshimura
    Parasitology Research, 1997, 83 : 583 - 590
  • [36] Nasal polyposis: eosinophils and interleukin-5
    Kramer, MF
    Rasp, G
    ALLERGY, 1999, 54 (07) : 669 - 680
  • [37] Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations
    Diego Bagnasco
    Matteo Ferrando
    Marco Caminati
    Alice Bragantini
    Francesca Puggioni
    Gilda Varricchi
    Giovanni Passalacqua
    Giorgio Walter Canonica
    Drug Safety, 2017, 40 : 559 - 570
  • [38] INTERLEUKIN-5, EOSINOPHILS AND BRONCHIAL HYPERREACTIVITY
    ROBINSON, DS
    CLINICAL AND EXPERIMENTAL ALLERGY, 1993, 23 (01): : 1 - 3
  • [39] MODULATION OF EOSINOPHIL CHEMOTAXIS BY INTERLEUKIN-5
    WARRINGA, RAJ
    SCHWEIZER, RC
    MAIKOE, T
    KUIJPER, PHM
    BRUIJNZEEL, PLB
    KOENDERMAN, L
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1992, 7 (06) : 631 - 636
  • [40] Interleukin-5, interleukin-5, and granulocyte-macrophage colony-stimulating factor expression in nasal polyps
    Allen, JS
    Eisma, R
    Leonard, G
    Kreutzer, D
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1997, 18 (04) : 239 - 246